Incidence and Cost of Hospital Admissions Secondary to Drug Interactions Involving Theophylline

Hamilton, Robert A.; Gordon, Tammy S.

doi:10.1177/106002809202601202

Cited by 20 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To quantify the impact of chemotherapy-induced toxicity, the incidence method as described by Hamilton was used in the current study. 11 Briefly, the incidence method requires an estimate of the incremental cost of a particular toxic event and the percent incidence of the event in a group of patients receiving treatment with the drug in question. This cost estimate is then multiplied by the percent incidence.…”

Section: Cost Consequence Analysismentioning

confidence: 99%

“…Of the three agents, nabpaclitaxel had the highest drug cost per cycle which translated to the highest cost per course when the median number of cycles were incorporated into the analysis (Table 5). However, when the cost impact of side-effects was estimated through the application of the incidence method, 11 the data revealed that nab-paclitaxel would require the least amount of health care resources for the management of side-effects ($597 vs. paclitaxel at $1227 vs. docetaxel at $2626). Furthermore, it is important to point out that the quality of life benefit (i.e., in the form of a utility gain) secondary to nab-paclitaxel's improved side-effect profile was not yet applied.…”

Section: Cost Consequence Analysismentioning

confidence: 99%

See 1 more Smart Citation

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

Dranitsaris

Cottrell

Spirovski

et al. 2008

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

Section: Cost Consequence Analysismentioning

confidence: 99%

Section: Cost Consequence Analysismentioning

confidence: 99%

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

Dranitsaris

Cottrell

Spirovski

et al. 2008

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…For example, there are several reports of phenytoin toxicity in patients also taking cimetidine 26 . Cimetidine has also been reported to be involved in toxic drug–drug interactions with theophylline, 28 triazolam, 29 procainamide, 30 and lidocaine 31 . As a result of its high risk for potentially toxic drug–drug interactions, cimetidine must be used with caution in patients who are receiving other medications.…”

Section: Clinically Important Drug–drug Interactionsmentioning

confidence: 99%

Review article: drug interactions with agents used to treat acid‐related diseases

Humphries

Merritt

1999

Aliment Pharmacol Ther

106

View full text Add to dashboard Cite

Patients with acid-related diseases often need to take multiple medications. Treatment of Helicobacter pylori infection often includes either a histamine type 2 (H2)-receptor antagonist or a proton pump (H+,K(+)-ATPase) inhibitor (proton pump inhibitor), administered in conjunction with one or more antimicrobials. Also, treatment for acid-related diseases often requires extended therapy during which many concomitant medications may be administered for concurrent disease states. Polypharmacy may be the result, particularly in elderly patients, who are at increased risk for both acid-related and many other diseases. Thus, it is important to understand the potential for clinically significant drug-drug interactions in this setting. H2-receptor antagonists and proton pump inhibitors can influence the pharmacokinetic profiles of other commonly administered medications by elevating intragastric pH, which can alter drug absorption, and by interacting with the cytochrome P (CYP) 450 enzyme system, which can affect drug metabolism and clearance. Such interactions are particularly important when they affect the pharmacokinetics of drugs with narrow therapeutic ranges (e.g. warfarin, digoxin). In these cases, drug-drug interactions can result in significant toxicity and even death. There are marked differences among H2-receptor antagonists and proton pump inhibitors in their potential for such interactions. The oldest drugs in each class, cimetidine and omeprazole, respectively, have the greatest potential to alter CYP activity and change the pharmacokinetics of other drugs. The most recently developed H2-receptor antagonist, famotidine, and the newer proton pump inhibitors, rabeprazole and pantoprazole, are much less likely to induce or inhibit CYP and thereby change the metabolism of other medications. These differences are important when choosing medications for the safe treatment of patients with acid-related diseases.

show abstract

“…To measure the cost of these treatment-related toxicities, the incidence method developed by Hamilton and Gordon was used. 19 To apply this method, the incidence (%) of the event reported in a group of patients receiving the treatment is needed along with the cost to treat the event. The percent incidence is then multiplied by the cost per event.…”

Section: Methodsmentioning

confidence: 99%

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

Dranitsaris¹,

Yu²,

King³

et al. 2015

CEOR

View full text Add to dashboard Cite

BackgroundPaclitaxel and docetaxel are commonly used for metastatic breast cancer in the People’s Republic of China. To improve the safety and efficacy of paclitaxel, an albumin-bound formulation (nab) is now available in the People’s Republic of China (Abraxane®). To provide health economic data for the key stakeholders, a cost-utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel, was conducted.MethodsA meta-analysis of clinical outcomes Phase III trials comparing nab-paclitaxel (260 mg/m2 every [q] 3 weeks) or branded docetaxel (100 mg/m2 q 3 weeks), to solvent-based branded paclitaxel (175 mg/m2 q 3 weeks) was undertaken to provide safety and clinical data. Resource use data for the delivery of anticancer therapy and for the treatment of grade 3/4 toxicity was collected from a time and motion study conducted in three Chinese cancer centers and from a survey of clinicians. Using the Time Trade-Off technique, health utility estimates were derived from interviewing 28 breast cancer patients from one cancer center in the People’s Republic of China. All costs were reported in 2014 US dollars.ResultsNab-paclitaxel had the most favorable safety profile, characterized with the lowest incidence of grade 3/4 neutropenia, febrile neutropenia, anemia, and stomatitis. When the median number of cycles delivered from the clinical trials was applied, nab-paclitaxel had a cost per course of $19,752 compared with $8,940 and $13,741 for paclitaxel and docetaxel, respectively. As an alternative to paclitaxel, the cost per quality-adjusted life-year (QALY) gained with nab-paclitaxel suggested better value than with docetaxel ($57,900 vs $130,600).ConclusionNab-paclitaxel appears to be a cost-effective option compared with docetaxel and paclitaxel, for metastatic breast cancer in the People’s Republic of China.

show abstract

Incidence and Cost of Hospital Admissions Secondary to Drug Interactions Involving Theophylline

Abstract: The incidence of hospital admissions secondary to theophylline drug interactions with cimetidine, ciprofloxacin, or erythromycin is low, but the admissions represent considerable expense, even when distributed among all patients at risk for the interactions.

Cited by 20 publications

References 8 publications

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

Review article: drug interactions with agents used to treat acid‐related diseases

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

Contact Info

Product

Resources

About